ArticleDisease models & mechanisms2018
Idebenone and coenzyme Q
Article in Disease models & mechanisms, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Alleviating effects of coenzyme Q10 supplements on biomarkers of inflammation and oxidative stress: results from an umbrella meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Lipidomic Profiling of Colonic Contents in Mice with AcuteMicroorganisms · 2026Article
- Lecithin coenzyme Q10 restores mitochondrial dynamics and alleviates hepatic dysfunction in high-fat Diet-Fed db/db mice.Lipids in health and disease · 2025Article
- Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies.Molecular and cellular biochemistry · 2025Review
- The Role of Mitochondrial Quality Control in Liver Diseases: Dawn of a Therapeutic Era.International journal of biological sciences · 2025Review
- Idebenone: Clinical Potential Beyond Neurological Diseases.Drug design, development and therapy · 2025Review
- Effect of Coenzyme Q10 Supplementation on Lipid and Glycaemic Profiles: An Umbrella Review.Journal of cardiovascular development and disease · 2024Review
- Triiodothyronine (T3) promotes browning of white adipose through inhibition of the PI3K/AKT signalling pathway.Scientific reports · 2024Article
- Gastroprotective and microbiome-modulating effects of ubiquinol in rats with radiation-induced enteropathy.Animal microbiome · 2024Article
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases.Genes & diseases · 2024Review
- The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber's Hereditary Optic Neuropathy.Biomedicines · 2024Review
- Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).International journal of molecular sciences · 2023Review
- Transcriptomic (DNA Microarray) and Metabolome (LC-TOF-MS) Analyses of the Liver in High-Fat Diet Mice after Intranasal Administration of GALP (Galanin-like Peptide).International journal of molecular sciences · 2023Article
- The advancements in targets for ferroptosis in liver diseases.Frontiers in medicine · 2023Review
- Coenzyme Q10 Stimulate Reproductive Vatality.Drug design, development and therapy · 2023Review
- CoQ Regulates Brown Adipose Tissue Respiration and Uncoupling Protein 1 Expression.Antioxidants (Basel, Switzerland) · 2022Article
- Systematic Understanding of Anti-Aging Effect of Coenzyme Q10 on Oocyte Through a Network Pharmacology Approach.Frontiers in endocrinology · 2022Article
- Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice.Journal of biochemical and molecular toxicology · 2021Article
- Novel Short-Chain Quinones to Treat Vision Loss in a Rat Model of Diabetic Retinopathy.International journal of molecular sciences · 2021Article
- Idebenone: When an antioxidant is not an antioxidant.Redox biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Current peroxisome proliferator-activated receptor (PPAR)-targeted drugs, such as the PPARγ-directed diabetes drug rosiglitazone, are associated with undesirable side effects due to robust agonist activity in non-target tissues. To find new PPAR ligands with fewer toxic effects, we generated transgenic zebrafish that can be screened in high throughput for new tissue-selective PPAR partial agonists. A structural analog of coenzyme Q
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.